Genomic sequence analysis linked response to neoadjuvant therapy including Abraxane in triple negative breast cancer (TNBC) to a unique molecular signature.
The results to be presented during the breast cancer session at ASCO 2018 Annual Meeting
CHICAGO, IL – June 2, 2018 – NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present findings on a genome-based investigation in the neoadjuvant GeparSepto trial for breast cancer treatment during the breast cancer session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event bringing together 30,000 oncology professionals from June 1-5, 2018 at McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at booth #7147 during the event. In this seminal study, genomic sequence analysis linked response to neoadjuvant therapy including Abraxane in triple negative breast cancer to a unique molecular signature: defective homologous recombination DNA repair. This signature is often, but not always driven by mutations in the BRCA genes.
“We are excited to present results that might be used to identify tumors with an increased response rate to neoadjuvant chemotherapy,” said Patrick Soon-Shiong, MD, founder of NantWorks. “The clinical relevance of mutational signatures has not been studied to a great extent. As such, we’re looking forward to continuing this area of study to determine the clinical behavior of breast cancer.”
Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer – a genome-based investigation in the neoadjuvant GeparSepto trial, Abstract #574
WHO: NantOmics, LLC
WHAT: Breast Cancer—Local/Regional/Adjuvant Session
WHEN: June 2, 8:00-11:30 AM CST
WHERE: Hall A, McCormick Place
This study investigated the individual patterns of mutational signatures that determine the clinical behavior of breast cancer (BC), in particular response to neoadjuvant chemotherapy. In the GeparSepto study, women with primary invasive BC were randomized to either nab-paclitaxel or solvent-based paclitaxel followed by EC. Pretherapeutic FFPE core biopsies of HER2-neg BC were used for whole genome/exome sequencing and mutational signatures were identified as described by Alexandrov et al. As a result, whole-exome sequencing in breast cancer FFPE core biopsies from clinical cohorts can be used to identify mutational signatures. The pattern of these signatures, in particular the presence of BRCA-related (Sig3) and APOBEC-related (Sig13), reflect the clinical behavior of breast cancer and may be used to identify tumors with an increased response rate to neoadjuvant chemotherapy.
NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular analysis capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular analysis company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumor sample used for genomic analysis. For more information please visit www.nantomics.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.